Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Maintenance in ED-SCLC
NCT01159327Phase 2Terminated
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2010
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) comparing Sorafenib Maintenance with Observation (2 arms). Primary endpoint: Progression-Free Survival. Started Dec 2010; status: terminated.
02
Drugs
sorafenib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01159327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01159327.